T. Rowe Price Investment Management Inc. Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT)

T. Rowe Price Investment Management Inc. lifted its position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 2,511.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,420,920 shares of the company's stock after buying an additional 5,213,370 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 4.66% of Applied Therapeutics worth $4,642,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of APLT. Barclays PLC boosted its stake in shares of Applied Therapeutics by 186.1% in the 3rd quarter. Barclays PLC now owns 200,012 shares of the company's stock worth $1,702,000 after buying an additional 130,102 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Applied Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company's stock worth $268,000 after buying an additional 47,983 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares during the last quarter. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics in the 4th quarter worth $35,000. Finally, Swiss National Bank purchased a new position in shares of Applied Therapeutics in the 4th quarter worth $126,000. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

Applied Therapeutics Price Performance

APLT stock opened at $0.40 on Monday. The company has a market cap of $56.45 million, a P/E ratio of -0.25 and a beta of 1.88. Applied Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $10.62. The stock's fifty day moving average price is $0.46 and its 200-day moving average price is $2.74.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. As a group, analysts expect that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.